Literature DB >> 11590249

Anaemia in end-stage renal disease: pathophysiological considerations.

K U Eckardt1.   

Abstract

Anaemia is a frequent complication of many diseases but the mechanisms that link reduced blood oxygen content to the long-term consequences of anaemia are incompletely understood. The maintenance of oxygen supply to the tissues during anaemia involves complex cardiovascular adaptations, including an increase in cardiac output, reduced peripheral resistance and increased oxygen extraction from haemoglobin (Hb). In addition, hypoxia-inducible factors are associated with the transcriptional activation of genes involved in adaptive mechanisms that increase oxygen delivery and provide alternative metabolic pathways. The complex pathophysiology of chronic kidney disease alters the adaptations to anaemia in uraemic patients. The increased cardiac output induced by anaemia is associated with left ventricular hypertrophy and cardiac disease in renal patients. Alterations in endothelial cell function, common in renal disease, may diminish endothelium-induced vasodilatation, increase the risk of atherosclerosis and impair angiogenesis. Many potential reasons for erythropoietin-induced hypertension in uraemic patients have been postulated, including increased blood viscosity as haematocrit rises, a reversal of hypoxic vasodilatation, increased blood volume that is not compensated by haemodialysis, ultrafiltration and impaired nitric oxide synthesis, preventing vascular relaxation in response to increased blood viscosity. In view of this impaired vascular reactivity, rapid increases in haematocrit should be avoided during epoetin treatment. As the interaction between anaemia and uraemia is very complex, it is not possible to derive the optimal Hb concentration for individual patients by using simple physiological or pathophysiological models and there is a need for good randomized controlled clinical trials to address this issue.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11590249     DOI: 10.1093/ndt/16.suppl_7.2

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  6 in total

1.  The relation between hemoglobin variability and carotid intima-media thickness in chronic hemodialysis patients.

Authors:  Safa Ersen Ganidagli; Orcun Altunoren; Ertuğrul Erken; Ismet Onder Isık; Berivan Ganidagli; Necmi Eren; Yasemin Coskun Yavuz; Ozkan Gungor
Journal:  Int Urol Nephrol       Date:  2017-07-15       Impact factor: 2.370

Review 2.  Hemodialysis-induced cardiovascular disease.

Authors:  Shadi Ahmadmehrabi; W H Wilson Tang
Journal:  Semin Dial       Date:  2018-04-06       Impact factor: 3.455

3.  Inhibition of bone morphogenetic protein signaling attenuates anemia associated with inflammation.

Authors:  Andrea U Steinbicker; Chetana Sachidanandan; Ashley J Vonner; Rushdia Z Yusuf; Donna Y Deng; Carol S Lai; Kristen M Rauwerdink; Julia C Winn; Borja Saez; Colleen M Cook; Brian A Szekely; Cindy N Roy; Jasbir S Seehra; Gregory D Cuny; David T Scadden; Randall T Peterson; Kenneth D Bloch; Paul B Yu
Journal:  Blood       Date:  2011-03-10       Impact factor: 22.113

4.  Sitagliptin on Carotid Intima-Media Thickness in Type 2 Diabetes Mellitus Patients and Anemia: A Subgroup Analysis of the PROLOGUE Study.

Authors:  Zhengri Lu; Genshan Ma; Lijuan Chen
Journal:  Mediators Inflamm       Date:  2020-05-11       Impact factor: 4.711

5.  Association of plasma macrophage colony-stimulating factor with cardiovascular morbidity and all-cause mortality in chronic hemodialysis patients.

Authors:  Xuan Deng; Qian Yang; Yuxi Wang; Yi Yang; Guangchang Pei; Han Zhu; Jianliang Wu; Meng Wang; Zhi Zhao; Huzi Xu; Cheng Zhou; Yi Guo; Ying Yao; Zhiguo Zhang; Wenhui Liao; Rui Zeng
Journal:  BMC Nephrol       Date:  2019-08-16       Impact factor: 2.388

6.  Epidemiology and outcomes in patients with anemia of CKD not on dialysis from a large US healthcare system database: a retrospective observational study.

Authors:  Lois Lamerato; Glen James; Heleen van Haalen; Katarina Hedman; James A Sloand; Amy Tang; Eric T Wittbrodt; Jerry Yee
Journal:  BMC Nephrol       Date:  2022-04-30       Impact factor: 2.585

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.